Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) treatments targeting epidermal growth factor receptor (EGFR) face challenges due to drug resistance.
• Developing novel therapeutic strategies is crucial for overcoming NSCLC treatment resistance.

Purpose of the Study:

• To investigate the efficacy of metapristone, a metabolite of RU486, in inhibiting NSCLC cell proliferation.
• To elucidate the molecular mechanisms underlying metapristone's anti-cancer effects in NSCLC.

Main Methods:

• Assessing metapristone's effect on NSCLC cell lines with wild-type and mutated EGFR.
• Analyzing the impact of metapristone on key signaling proteins including EGFR, PTEN, AKT, ERK, Bcl-2, caspase-3, and PARP.
• Evaluating metapristone's effect on cell cycle progression and NSCLC xenograft growth in vivo.

Main Results:

• Metapristone suppressed proliferation in various NSCLC cell lines, irrespective of EGFR mutation status.
• Metapristone downregulated EGFR, PTEN, AKT, and ERK, inhibited Bcl-2, and activated caspase-3 and PARP.
• Metapristone induced G0-G1 cell cycle arrest and reduced NSCLC xenograft growth by decreasing PCNA and EGFR expression.

Conclusions:

• Metapristone effectively suppresses NSCLC proliferation by inhibiting EGFR-mediated PI3K/AKT pathways and promoting apoptosis.
• Metapristone demonstrates potential as a novel therapeutic agent for EGFR-overexpressed NSCLC.